Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX

$553.15

Updated: 03/11/2026, 03:57:12

Market Cap
$140.20B
Sector
Healthcare
Industry
Biotechnology
Country
US

No historical data available

Company Profile

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.

USD
NASDAQ
CEO: Reshma Kewalramani
Employees: 6,400
https://www.vrtx.com
Asset Summaries
Latest generated summaries for VRTX

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
VRTX-10-k-fy2025.html4.8 MBtext/htmlENFiled 13/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 62 KPI observations

Revenue

$12.0B

FY 2025 · Reported

Net income

$4.0B

FY 2025 · Reported

Gross margin

86.2%

FY 2025 · Calculated

Free cash flow

$3.2B

FY 2025 · Calculated

R&D intensity

N/A

FY — · Reported

Share repurchases

$2.0B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

Five CF medicines led by TRIKAFTA/KAFTRIO; ALYFTREK launch
CASGEVY commercialization risk
JOURNAVX (suzetrigine) acute pain launch risk
JOURNAVX non-opioid acute pain medicine
CASGEVY CRISPR gene-edited cell therapy
Product families and revenue recognition triggers

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Global biotech focused on specialty markets

Global biotechnology company; approved medicines for CF, SCD, TDT, acute pain; pipeline across additional serious diseases

95%
Source evidence
“We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets.”

Single operating segment

One operating segment: pharmaceuticals (sole reporting unit for goodwill testing)

90%
Source evidence
“we have one operating segment, pharmaceuticals, which is our only reporting unit.”

International and CASGEVY distribution channels

International sales primarily through distributor arrangements; CASGEVY sold directly to authorized treatment centers in certain markets

90%
Source evidence
“We make international sales primarily through distributor arrangements and to retail pharmacies, as well as to hospitals and clinics, many of which are government-owned or supported customers.”

Five CF medicines led by TRIKAFTA/KAFTRIO; ALYFTREK launch

Five CF medicines treat ~75% of CF patients in US/Europe/Australia/Canada; ALYFTREK approved in 8 countries

95%
Source evidence
“Collectively, our five CF medicines, led by TRIKAFTA/KAFTRIO, are being used to treat nearly three quarters of the people with CF in the U.S., Europe, Australia, and Canada.”

CASGEVY commercialization risk

CASGEVY gene-edited cell therapy; manufacturing cost as % of revenue significantly higher than CF medicines

95%
Source evidence
“the cost of manufacturing CASGEVY as a percentage of revenue is significantly higher than for our CF medicines.”

JOURNAVX (suzetrigine) acute pain launch risk

JOURNAVX for acute pain; NaV1.8/NaV1.7 inhibitors for acute and neuropathic pain

95%
Source evidence
“A portion of the value attributed to our company by investors is based on the expected commercial success of JOURNAVX for acute pain and on our development programs for both acute and peripheral neuropathic pain.”

JOURNAVX non-opioid acute pain medicine

JOURNAVX approved in U.S. for moderate-to-severe acute pain; launch ongoing

95%
Source evidence
“JOURNAVX, our selective non-opioid NaV1.8 pain signal inhibitor, is approved in the U.S. for the treatment of people with moderate-to-severe acute pain.”

CASGEVY CRISPR gene-edited cell therapy

CASGEVY approved in 10 markets for SCD/TDT (ages 12+)

95%
Source evidence
“CASGEVY, our ex-vivo, non-viral CRISPR/Cas9 gene-edited cell therapy, is approved in the U.S., the E.U., the U.K., the Kingdom of Saudi Arabia ("Saudi Arabia"), the Kingdom of Bahrain ("Bahrain"), Qatar, the United Arab Emirates (the "UAE"), Kuwait, Switzerland and Canada”

Product families and revenue recognition triggers

CF products and JOURNAVX recognized on delivery; CASGEVY recognized upon infusion

93%
Source evidence
“upon delivery to customers for our small molecule products, including our CF products and JOURNAVX, and upon infusion of our gene-therapy products, including CASGEVY”

ALYFTREK reimbursement geographies

ALYFTREK reimbursed in 12 countries/jurisdictions; access efforts ongoing in additional countries

90%
Source evidence
“ALYFTREK is reimbursed for eligible people with CF in the U.S., England, Ireland, Germany, Denmark, Northern Ireland, Norway, Wales, Italy, Australia, New Zealand and Luxembourg.”

Total revenues 2025 vs 2024

Total revenues $12.0B in 2025 vs $11.0B in 2024

95%
Source evidence
“In 2025, our total revenues increased to $12.0 billion as compared to $11.0 billion in 2024, primarily due to continued strong demand for TRIKAFTA/KAFTRIO as well as contributions from our launches of ALYFTREK, JOURNAVX and CASGEVY.”

Operations and dependencies

Limited-facility concentration and flood zone exposure

Massachusetts coastal flood zone houses HQ and key logistics/laboratory/manufacturing space

92%
Source evidence
“our corporate headquarters, as well as additional leased space that we use for certain logistical and laboratory operations and manufacturing, are located in a flood zone along the Massachusetts coast.”

Lonza T1D cell therapy manufacturing agreement

Strategic agreement with Lonza to build/operate 130,000 sq ft New Hampshire facility for T1D cell therapy; lease payments begin Q1 2026

94%
Source evidence
“a strategic agreement with Lonza to support the manufacture of T1D cell therapy product candidates, pursuant to which we have partnered with Lonza to build a 130,000 square foot dedicated new facility operated by Lonza in New Hampshire”

Reliance on CROs, CMOs, logistics providers

Dependence on CROs, CMOs and logistics providers with limited substitutability

93%
Source evidence
“we rely on third parties such as CROs for the day-to-day management and oversight of our clinical trials, on CMOs for active ingredient manufacturing and finishing operations, and on logistics providers for the distribution of our products.”

Employees as of December 31, 2025

Approximately 6,400 employees at December 31, 2025 (~5,200 U.S., ~1,200 outside U.S.); no U.S. collective bargaining coverage

98%
Source evidence
“As of December 31, 2025, we had approximately 6,400 employees. Of these employees, approximately 5,200 were based in the U.S. and approximately 1,200 were based outside the U.S.”

Positioning and strategy

Alpine acquisition treated as asset acquisition

$5.0B 2024 acquisition of Alpine accounted for as asset acquisition; $4.4B attributed to povetacicept expensed to AIPR&D in 2024

95%
Source evidence
“we accounted for our $5.0 billion acquisition of Alpine in 2024 as an asset acquisition because povetacicept, Alpine's lead molecule, represented substantially all of the fair value”

Acquisition of Alpine (povetacicept)

Acquired Alpine and its lead asset, povetacicept

95%
Source evidence
“including our acquisition of Alpine and its lead asset, povetacicept”

Business development and liquidity strategy

Will consider all financing opportunities to strengthen long-term liquidity; agreements carry contingent milestone and royalty obligations

88%
Source evidence
“We will continue to manage our capital structure and will consider all financing opportunities, whenever they may occur, that could strengthen our long-term liquidity profile.”

Risks, financing, and outlook

Clinical trial cost drivers

Clinical trial costs depend on size, number, length of trials and increase as candidates move to later stages

88%
Source evidence
“Our clinical trial costs are dependent on, among other things, the size, number, and length of our clinical trials.”

Credit agreement repayment 2027

Any borrowings under existing credit agreement must be repaid in 2027

92%
Source evidence
“To the extent we borrow amounts under our existing credit agreement, we would be required to repay any outstanding principal amounts in 2027.”

US-China biotechnology legislation risk

Proposed US restrictions on Chinese biotech service providers could affect operations

90%
Source evidence
“U.S. legislation has been introduced to limit certain U.S. biotechnology companies from using equipment or services from select Chinese biotechnology companies.”

Share repurchase authorization $3.4B

$3.4 billion remaining under share repurchase program approved May 2025; no expiration date

95%
Source evidence
“we had $3.4 billion remaining authorization available under the share repurchase program that our Board of Directors approved in May 2025. The program does not have an expiration date”

CF patient growth drivers

Number of CF patients on Vertex medicines expected to grow via approvals, reimbursement, younger patients, survival, geographies

90%
Source evidence
“We expect that the number of people with CF taking our medicines will continue to grow through new approvals and reimbursement agreements, treatment of younger patients, increased survival and expansion into additional geographies.”

Cash position

Cash, cash equivalents and marketable securities $12.3B at Dec 31, 2025 vs $11.2B at Dec 31, 2024

95%
Source evidence
“Our total cash, cash equivalents and marketable securities increased to $12.3 billion as of December 31, 2025 as compared to $11.2 billion as of December 31, 2024”

TRIKAFTA/ALYFTREK boxed warning for liver injury

Dec 2024 FDA boxed warning on liver injury/failure for TRIKAFTA and ALYFTREK

95%
Source evidence
“in December 2024, the FDA required us to modify the TRIKAFTA label by revising information regarding liver injury and liver failure and moving that information from the “warnings and precautions” section to a “boxed warning” section; the FDA required similar language in the ALYFTREK label.”

Ex-U.S. government reimbursement dependency

Outside the U.S., product success depends largely on government reimbursement; E.U. member states can restrict reimbursement and control prices; ex-U.S. prices often below U.S. net price

95%
Source evidence
“Reimbursement discussions in foreign countries often result in a reimbursement price that is lower than the net price that companies can obtain for the product in the U.S.”

U.S. drug pricing reform pressure

U.S. pricing/reimbursement pressure from Manufacturer Discount Program, state PDABs (Colorado, Maryland, Washington, Minnesota), MFN pricing focus, and CMS's proposed GUARD model

95%
Source evidence
“GUARD is a proposed mandatory model that would assess rebates for certain drugs payable under Medicare Part D if the prices exceed those paid in economically comparable countries.”

US drug pricing policy exposure (IRA, PDABs, MFN, GUARD Model)

Exposure to IRA, state PDABs (Colorado TRIKAFTA review), MFN pricing and CMS GUARD Model

92%
Source evidence
“in August 2023, the Colorado PDAB selected five drugs for an affordability review, including TRIKAFTA.”

Anti-corruption laws (FCPA, U.K. Bribery Act)

Subject to FCPA and U.K. Bribery Act 2010 governing payments to government officials

90%
Source evidence
“In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official.”

Healthcare fraud and abuse laws (AKS, FCA)

Subject to U.S. Anti-Kickback Statute and False Claims Act with penalties including exclusion from Medicare/Medicaid

90%
Source evidence
“Violations of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including fines and civil monetary penalties, as well as by the possibility of exclusion from federal healthcare programs (including Medicare and Medicaid).”

Privacy and data protection laws

Subject to GDPR and California privacy laws; collecting sensitive health data; enforcement and fines increasing

90%
Source evidence
“the E.U. General Data Protection Regulation ("GDPR") imposes obligations on us with respect to our processing of personal data and the cross-border transfer of such data”

Revenue concentration in CF medicines

Substantially all net product revenues derived from cystic fibrosis medicines

98%
Source evidence
“Substantially all our net product revenues have been derived from the sale of our CF medicines.”

cGMP manufacturing regulation and supplier qualification

Manufacturing (including CMOs) subject to FDA/EMA cGMP; regulators may shut down non-compliant facilities; supplier qualification delays possible

95%
Source evidence
“The manufacturing process for pharmaceutical products is highly regulated and regulators may shut down manufacturing facilities that they observe are not complying with regulations.”

Ex-US government price controls and reimbursement timing

Challenges obtaining timely ex-US reimbursement; cost-containment legislation risk

90%
Source evidence
“We have experienced challenges in obtaining timely reimbursement for our products in various countries outside the U.S.”

Post-approval safety reporting obligations

FDA can mandate labeling changes, REMS, new post-marketing studies, or suspend/withdraw approval based on new safety information

90%
Source evidence
“the FDA can mandate product labeling changes, impose risk evaluation and mitigation strategies, require new post-marketing studies (including additional clinical trials) or suspend or withdraw approval of the product.”

Shared API risk across CF products

All CF products share at least one API, creating cross-product safety risk

90%
Source evidence
“Each of our CF products shares at least one active pharmaceutical ingredient with another of our products.”

cGMP manufacturing compliance and inspection risk

cGMP compliance and FDA/foreign inspection risk for company and CMOs

88%
Source evidence
“If, as a result of these inspections, a regulatory authority determines that the equipment, facilities, laboratories or processes do not comply with applicable regulations and conditions of product approval, the regulatory authority may suspend the manufacturing operations.”

Talent competition in biotechnology

Recruiting and retaining skilled, experienced employees is important given intense biotechnology industry competition

85%
Source evidence
“The biotechnology industry is very competitive, and recruiting and retaining such employees is important to the continued success of our business.”

Material exposure graph

CF medicines
Revenue Exposure

Substantially all net product revenues come from CF medicines, making revenue highly concentrated in one franchise.

Relevance 98·Dependency 95·Confidence 98
Source evidence
“Substantially all our net product revenues have been derived from the sale of our CF medicines.”
TRIKAFTA/KAFTRIO
Revenue Exposure

2025 revenue growth primarily driven by continued strong TRIKAFTA/KAFTRIO demand; CF franchise is dominant revenue source.

Relevance 95·Dependency 90·Confidence 95
Source evidence
“primarily due to continued strong demand for TRIKAFTA/KAFTRIO as well as contributions from our launches of ALYFTREK, JOURNAVX and CASGEVY”
CF patients and payers
Customer Exposure

Revenue depends on CF patients (~75% of CF population treated) and reimbursement agreements across geographies.

Relevance 90·Dependency 85·Confidence 90
Source evidence
“are being used to treat nearly three quarters of the people with CF in the U.S., Europe, Australia, and Canada”
U.S. drug pricing and reimbursement regulation
Regulatory Exposure

Mandatory U.S. pricing initiatives could reduce Vertex product pricing and reimbursement

Relevance 90·Dependency 85·Confidence 95
Source evidence
“implementation of mandatory initiatives could result in reduced pricing and reimbursement for our products.”
Specialty pharmacies, specialty distributors, major wholesalers
Customer Exposure

A limited number of US specialty pharmacies, distributors and wholesalers account for the largest portion of total revenues.

Relevance 85·Dependency 80·Confidence 95
Source evidence
“which account for the largest portion of our total revenues”
Ex-U.S. government reimbursement systems
Regulatory Exposure

Non-reimbursed products are largely inaccessible to ex-U.S. patients; reimbursement terms and delays directly affect ex-U.S. revenue

Relevance 85·Dependency 80·Confidence 90
Source evidence
“the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed by their governments.”
Medicaid Drug Rebate Program
Regulatory Exposure

Medicaid rebate obligations are the most significant revenue-recognition estimate, with a $1,777.6M accrual balance at 12/31/2025.

Relevance 85·Dependency 75·Confidence 95
Source evidence
“Our most significant estimate relates to determining amounts due pursuant to the Medicaid Drug Rebate Program”
Lonza
Supplier Dependency

Lonza operates a dedicated 130,000 sq ft New Hampshire facility for T1D cell therapy manufacture under a strategic agreement.

Relevance 85·Dependency 70·Confidence 94
Source evidence
“a strategic agreement with Lonza to support the manufacture of T1D cell therapy product candidates”
US drug pricing laws (IRA, PDABs, MFN/GUARD)
Regulatory Exposure

US pricing/access governed by Medicare/Medicaid rules (ACA, IRA), PDABs, and potential MFN/GUARD Model pricing could reduce pricing and reimbursement.

Relevance 85·Dependency 70·Confidence 92
Source evidence
“initiatives by the U.S. government to impose most-favored-nation pricing on U.S. prescription drug prices in government programs, including the recently proposed GUARD Model by the CMS.”
CROs, CMOs, logistics providers
Supplier Dependency

Critical R&D, API manufacturing/finishing, and distribution depend on third parties that may not be replaceable timely or on reasonable terms.

Relevance 80·Dependency 75·Confidence 92
Source evidence
“we may not be able to replace such third party in a timely manner, on commercially reasonable terms, or at all.”
ALYFTREK
Revenue Exposure

Newest CF medicine, launching and reimbursed across 12+ markets, contributing to 2025 revenue growth.

Relevance 80·Dependency 40·Confidence 90
Source evidence
“contributions from our launches of ALYFTREK, JOURNAVX and CASGEVY”
Payor rebates and government-mandated discounts
Revenue Exposure

Government, commercial, and private payor rebates/chargebacks materially reduce net product revenue and require significant estimates.

Relevance 75·Dependency 70·Confidence 90
Source evidence
“We are required to make estimates for our product revenues related to government, commercial, and private payor rebates, chargebacks, discounts and fees”
cGMP supplier qualification requirements
Supplier Dependency

Key component suppliers must be named in regulatory filings; qualifying new suppliers can cause significant delays

Relevance 75·Dependency 70·Confidence 90
Source evidence
“Suppliers of key components and materials must be named in the NDA or marketing authorization application filed with the regulatory authority for any product candidate for which we are seeking marketing approval, and significant delays can occur if the qualification of a new supplier is required.”
Reimbursement and patient access agreements
Regulatory Exposure

Growth in patients taking medicines depends on new approvals and reimbursement agreements; royalty rate changes affected cost of sales.

Relevance 75·Dependency 65·Confidence 85
Source evidence
“We expect that the number of people with CF taking our medicines will continue to grow through new approvals and reimbursement agreements”
Government-owned or supported international customers
Customer Exposure

International government-owned/supported customers have annual reimbursement caps requiring free goods beyond limits, affecting revenue deferral.

Relevance 75·Dependency 65·Confidence 90
Source evidence
“We have also entered into annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement we can receive for our products.”
JOURNAVX
Revenue Exposure

Investor value partly depends on JOURNAVX acute pain commercial success and NaV1.8/NaV1.7 neuropathic pain programs in a highly competitive market.

Relevance 75·Dependency 40·Confidence 90
Source evidence
“A portion of the value attributed to our company by investors is based on the expected commercial success of JOURNAVX for acute pain”
cGMP manufacturing regulations
Regulatory Exposure

Company, CMOs, and corporate partners subject to cGMP and inspections; deficiencies could suspend manufacturing operations.

Relevance 70·Dependency 65·Confidence 88
Source evidence
“we and our CMOs and corporate partners are subject to cGMP, as well as comparable regulations in other jurisdictions.”
CASGEVY
Revenue Exposure

CASGEVY gene-therapy revenue recognized upon infusion and sold via ATCs or specialty channels, with distinct distribution arrangements in certain markets.

Relevance 65·Dependency 50·Confidence 90
Source evidence
“upon infusion of our gene-therapy products, including CASGEVY”
CASGEVY
Revenue Exposure

CASGEVY launch generated $115.8M in 2025 with 64 patient infusions; scaling depends on reimbursed access.

Relevance 65·Dependency 20·Confidence 95
Source evidence
“In 2025, we recorded $115.8 million of CASGEVY product revenues.”
US-China biotech trade restrictions
Geopolitical Exposure

Proposed legislation limiting use of select Chinese biotechnology equipment/services creates uncertainty for service providers and trade relations.

Relevance 60·Dependency 40·Confidence 85
Source evidence
“U.S. legislation has been introduced to limit certain U.S. biotechnology companies from using equipment or services from select Chinese biotechnology companies”
Alpine (povetacicept acquisition)
Cost Driver

The $5.0B Alpine acquisition was expensed as AIPR&D ($4.4B for povetacicept) in 2024 due to asset-acquisition accounting.

Relevance 60·Dependency 40·Confidence 93
Source evidence
“$4.4 billion of the fair value attributed to povetacicept was expensed to AIPR&D in 2024.”
CASGEVY
Revenue Exposure

CASGEVY revenue depends on physician/patient/payor acceptance and complex manufacturing with significantly higher cost as % of revenue.

Relevance 60·Dependency 30·Confidence 88
Source evidence
“The future commercial success of CASGEVY depends on physicians, patients, or payors accepting it as medically useful, cost-effective, ethical, safe, and preferred”
SCD/TDT patients and payers
Revenue Exposure

CASGEVY revenue tied to reimbursed access (~90% of U.S. SCD/TDT patients) and patient infusion throughput.

Relevance 60·Dependency 25·Confidence 90
Source evidence
“approximately 90 percent of people with SCD or TDT in the U.S. have reimbursed access to CASGEVY”
Vertex Pharmaceuticals
Cost Driver

Cost of sales ratio affected by CF royalty rate, product mix, and network expansion/manufacturing process improvement investments.

Relevance 55·Dependency 50·Confidence 85
Source evidence
“partially offset by changes in our product mix, and investments in network expansion and manufacturing process improvements”
New Hampshire Lonza facility
Cost Driver

Lease payments for the dedicated T1D facility begin Q1 2026 and continue through the tenth anniversary of regulatory approval for commercial production.

Relevance 55·Dependency 50·Confidence 90
Source evidence
“Lease payments will begin in the first quarter of 2026 and continue through the tenth anniversary of the facility's regulatory approval for commercial production.”
Massachusetts coastal facilities
Manufacturing Dependency

HQ and key logistics, laboratory, and manufacturing space sit in a coastal flood zone; catastrophic loss would seriously harm operations.

Relevance 55·Dependency 45·Confidence 90
Source evidence
“If any of our major facilities were to experience a catastrophic loss due to an earthquake, flood, severe storms, fire or similar event, our operations would be seriously harmed.”
JOURNAVX
Revenue Exposure

JOURNAVX, newly approved non-opioid acute pain medicine, contributed to 2025 revenue growth; launch ongoing.

Relevance 55·Dependency 15·Confidence 90
Source evidence
“We are continuing our commercial launch of JOURNAVX for eligible adults.”
Full company information
Latest profile, trading, valuation, and identifier data stored for VRTX.
Share price
$553.15
Market cap
$140.20B
Exchange
NASDAQ
Currency
USD
CEO
Reshma Kewalramani
Employees
6,400
IPO date
24/07/1991
Beta
0.32
Last dividend
$0.00
Day range
$544.09 – $568.67
52-week range
$403.16 – $568.67
1-day performance
-1.03%
1-year performance
37.20%
Current drawdown (1Y)
-2.73%
CIK
0000875320
CUSIP
92532F100
ISIN
US92532F1003
Created
07/12/2025, 15:00:49
Last update
03/11/2026, 03:57:12

Track Vertex Pharmaceuticals Incorporated with an AI analyst

See which prediction-market events move VRTX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to VRTX from your Railway `news_articles` table.

Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts

Zacks Investment Research • STOCK • 11/06/2026, 20:51:06

Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors

Zacks Investment Research • STOCK • 10/06/2026, 21:01:51

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 10/06/2026, 16:22:17

Got $5,000? 1 Cash-Flow King to Buy and Hold Forever That Wall Street Is Completely Mispricing

24/7 Wall Street • STOCK • 02/06/2026, 14:02:49

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

Zacks Investment Research • STOCK • 01/06/2026, 12:01:24

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

Seeking Alpha • STOCK • 29/05/2026, 15:04:06

Vertex Pharmaceuticals Incorporated (VRTX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 19/05/2026, 18:40:44

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It

Zacks Investment Research • STOCK • 19/05/2026, 12:01:22

VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings

Zacks Investment Research • STOCK • 08/05/2026, 16:21:09

Vertex Pharmaceuticals (NASDAQ: VRTX) Shows Strong Growth Amidst Analyst Confidence and New Product Success

Market Data • Market Data • 06/05/2026, 13:04:11

Vertex Pharmaceuticals (NASDAQ:VRTX) Reports Strong Q1 Financial Results Driven by Cystic Fibrosis Treatment Growth

Market Data • Market Data • 05/05/2026, 02:01:23

Vertex Pharmaceuticals Incorporated (VRTX) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 05/05/2026, 01:03:22